antiviral news

Among the drugs recommended for use in outpatient settings are molnupiravir, favipiravir, nirmatrelvir with ritonavir, as well as other active substances.

A new study by several Chinese research teams has found that the oral nucleoside drug VV116 possesses strong antiviral activity against the Nipah virus (NiV), offering fresh hope in the fight against this emerging highly lethal infectious disease, according to the Wuhan Institute of Virology, Chinese Academy of Sciences.

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options.

A new study published in the journal of The Lancet Infectious Diseases showed that an efficient substitute for current COVID-19 therapies is ensitrelvir, a once-daily oral SARS-CoV-2 protease inhibitor developed by Shionogi. The current oral first-line medication for COVID-19, ritonavir-boosted nirmatrelvir, shares a molecular target (the primary protease) with ensitrelvir.

Pfizer’s oral COVID-19 antiviral Paxlovid received expanded approval from South Korea’s Ministry of Food and Drug Safety for use in patients with severe renal impairment, broadening the eligible treatment population.

The Indian government enforced a ban on oral nimesulide above 100 mg following ICMR advice, citing liver toxicity and public health risks.